Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

SARS-CoV-2 vaccine protection and deaths among US veterans during 2021
Barbara A. Cohn, Piera M. Cirillo, Caitlin C. Murphy, et al.
Science (2021) Vol. 375, Iss. 6578, pp. 331-336
Open Access | Times Cited: 241

Showing 1-25 of 241 citing articles:

SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact
Marc Lipsitch, Florian Krammer, Gili Regev‐Yochay, et al.
Nature reviews. Immunology (2021) Vol. 22, Iss. 1, pp. 57-65
Open Access | Times Cited: 305
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study
Cristina Menni, Anna May, Lorenzo Polidori, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 7, pp. 1002-1010
Open Access | Times Cited: 282
OMICRON (B.1.1.529): A new SARS‐CoV‐2 variant of concern mounting worldwide fear
Vikram Thakur, Radha Kanta Ratho
Journal of Medical Virology (2021) Vol. 94, Iss. 5, pp. 1821-1824
Open Access | Times Cited: 242
Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses
Tianyang Mao, Benjamin Israelow, Mario A. Peña-Hernández, et al.
Science (2022) Vol. 378, Iss. 6622
Open Access | Times Cited: 238
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
Jerald Sadoff, Glenda Gray, An Vandebosch, et al.
New England Journal of Medicine (2022) Vol. 386, Iss. 9, pp. 847-860
Open Access | Times Cited: 198
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection
Wei-Yu Chi, Yen-Der Li, Hsin‐Che Huang, et al.
Journal of Biomedical Science (2022) Vol. 29, Iss. 1
Open Access | Times Cited: 166
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022
Matthew Modes, Michael P. Directo, Michael Melgar, et al.
MMWR Morbidity and Mortality Weekly Report (2022) Vol. 71, Iss. 6, pp. 217-223
Open Access | Times Cited: 161
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
Alexander Wilhelm, Marek Widera, Katharina Grikscheit, et al.
EBioMedicine (2022) Vol. 82, pp. 104158-104158
Open Access | Times Cited: 145
Nanotechnology-based strategies against SARS-CoV-2 variants
Xiangang Huang, Edo Kon, Xuexiang Han, et al.
Nature Nanotechnology (2022) Vol. 17, Iss. 10, pp. 1027-1037
Open Access | Times Cited: 101
Impact of vaccination on the COVID-19 pandemic in U.S. states
Xiao Chen, Hanwei Huang, Jiandong Ju, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 84
Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States
Sally B. Coburn, Elizabeth Humes, Raynell Lang, et al.
JAMA Network Open (2022) Vol. 5, Iss. 6, pp. e2215934-e2215934
Open Access | Times Cited: 65
Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection Against the Delta Variant: A Retrospective Cohort Study
Priscilla Kim, Steven M. Gordon, Megan Sheehan, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e185-e190
Open Access | Times Cited: 64
Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
Karin Hardt, An Vandebosch, Jerald Sadoff, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1703-1715
Open Access | Times Cited: 63
Do vaccines protect against long COVID? What the data say
Heidi Ledford
Nature (2021) Vol. 599, Iss. 7886, pp. 546-548
Open Access | Times Cited: 62
Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines
Violette Mouro, Alain Fischer
Mucosal Immunology (2022) Vol. 15, Iss. 4, pp. 584-594
Open Access | Times Cited: 51
Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose
Laurent Rénia, Yun Shan Goh, Angéline Rouers, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 44
Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium
Veerle Stouten, Pierre Hubin, Freek Haarhuis, et al.
Viruses (2022) Vol. 14, Iss. 4, pp. 802-802
Open Access | Times Cited: 43
Nationwide Effectiveness of First and Second SARS-CoV2 Booster Vaccines During the Delta and Omicron Pandemic Waves in Hungary (HUN-VE 2 Study)
Zoltán Kiss, István Wittmann, Lőrinc Polivka, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 41
Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic
Rontgene Solante, Carlos Álvarez, Erlina Burhan, et al.
Expert Review of Vaccines (2022) Vol. 22, Iss. 1, pp. 1-16
Open Access | Times Cited: 41
Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial
Payam Tabarsi, Nassim Anjidani, Ramin Shahpari, et al.
Clinical Microbiology and Infection (2022) Vol. 29, Iss. 2, pp. 215-220
Open Access | Times Cited: 37
An extended interval between vaccination and infection enhances hybrid immunity against SARS-CoV-2 variants
Timothy A. Bates, Hans C. Leier, Savannah K. McBride, et al.
JCI Insight (2023) Vol. 8, Iss. 5
Open Access | Times Cited: 31
The Relationship of COVID-19 Vaccination with Mortality Among 86,732 Hospitalized Patients: Subpopulations, Patient Factors, and Changes over Time
Timothy B. Baker, Daniel M. Bolt, Stevens S. Smith, et al.
Journal of General Internal Medicine (2023) Vol. 38, Iss. 5, pp. 1248-1255
Open Access | Times Cited: 28
The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study
Cléber Vinícius Brito dos Santos, Naiara C. M. Valiati, Tatiana Guimarães de Noronha, et al.
The Lancet Regional Health - Americas (2023) Vol. 20, pp. 100465-100465
Open Access | Times Cited: 28
Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study
Anders Husby, Hanne Løvdal Gulseth, Petteri Hovi, et al.
BMJ Medicine (2023) Vol. 2, Iss. 1, pp. e000373-e000373
Open Access | Times Cited: 27
Page 1 - Next Page

Scroll to top